Table 1 Demographics, cardiovascular risk factors, and disease-related data in patients with RA
RA | |
|---|---|
(n = 338) | |
Age, years | 54 ± 10 |
Female, n (%) | 284 (84) |
BMI, kg/m2 | 29 ± 17 |
Abdominal circumference, cm | 96 ± 13 |
Cardiovascular data | |
CV risk factors, n (%) | |
Current smoker | 75 (22) |
Obesity | 98 (29) |
Hypertension | 100 (30) |
Diabetes mellitus | – |
Statins, n (%) | 95 (28) |
Lipids | |
Total cholesterol, mg/dl | 207 ± 37 |
Triglycerides, mg/dl | 138 ± 78 |
HDL cholesterol, mg/dl | 57 ± 15 |
LDL cholesterol, mg/dl | 122 ± 32 |
LDL:HDL cholesterol ratio | 2.29 ± 0.90 |
Non-HDL cholesterol, mg/dl | 150 ± 37 |
Lipoprotein (a), mg/dl | 35 (12–102) |
Apolipoprotein A1, mg/dl | 173 ± 30 |
Apolipoprotein B, mg/dl | 108 ± 46 |
Apo B:Apo A ratio | 0.64 ± 0.24 |
Apolipoprotein C-III, mg/dl | 4.6 (2.0–8.4) |
Disease-related data | |
Disease duration, years | 8 (4–15) |
CRP at time of study, mg/l | 2.6 (1.2–5.6) |
ESR at time of study, mm/1º h | 18 (7–32) |
Rheumatoid factor, n (%) | 250 (75) |
ACPA, n (%) | 204 (62) |
DAS28-ESR | 3.07 ± 1.34 |
DAS28-PCR | 2.70 ± 1.05 |
SDAI | 12 (7–19) |
CDAI | 8 (4–14) |
History of extraarticular manifestations, n (%) | 30 (11) |
Erosions, n (%) | 135 (44) |
Current drugs, n (%) | |
Prednisone | 120 (36) |
Prednisone doses, mg/day | 5 (3–5) |
NSAIDs | 160 (47) |
DMARDs | 288 (85) |
Methotrexate | 245 (72) |
Leflunomide | 72 (21) |
Hydroxychloroquine | 37 (11) |
Salazopyrin | 24 (7) |
Anti TNF therapy | 68 (20) |
Tocilizumab | 22 (7) |
Rituximab | 7 (2) |
Abatacept | 10 (3) |
Baricitinib | 5 (1) |
Tofacitinib | 10 (3) |